Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection,...

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas

HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent...

Checkout.com builds on APAC momentum with 71% TPV growth

Checkout.com builds on APAC momentum with 71% TPV growth

For the third consecutive year, Checkout.com has delivered more than 50% year-over-year net revenue growth across APAC. Alibaba, Trip.com, Temu, SHEIN, JD, Heytea, and NetEase are among the enterprise merchants now using Checkout.com's platform...

13 Degrees Wine Cellar Accelerates Growth Through Partnership with Scottish Auction House Whisky Hammer

13 Degrees Wine Cellar Accelerates Growth Through Partnership with Scottish Auction House Whisky Hammer

HONG KONG, March 30, 2026 /PRNewswire/ -- Hong Kong-based 13 Degrees Wine Cellar has announced a new partnership with Scottish online whisky auctioneer Whisky Hammer, supporting the company's continued diversification and strengthening its position...

StarCharge Energy Oceania Brings V2G Closer to Mainstream with CEC-Listed Halo 7.4kW

StarCharge Energy Oceania Brings V2G Closer to Mainstream with CEC-Listed Halo 7.4kW

Halo 7.4kW supports the next phase of V2G rollout in Australia SYDNEY, March 30, 2026 /PRNewswire/ -- StarCharge Energy Oceania today announced that its Halo 7.4kW V2G charger, model AD20074EU1923, has secured listing with the Clean Energy Council...

Creativity 2030 • 5th International Forum Held in Beijing

Creativity 2030 • 5th International Forum Held in Beijing

Exploring New Pathways for the Development of "AI + Culture" BEIJING, March 27, 2026 /PRNewswire/ -- On March 27, the Creativity 2030 • 5th International Forum was held in Shougang Park, Beijing. This forum, jointly organized by the International...

Unisound Posts Strong First Annual Results Since Listing: Revenue Surges Nearly 30%, H2 Loss Narrows Significantly by Over 90%, Profitability in Sight, Charting a New Course in Native Agentic AI

Unisound Posts Strong First Annual Results Since Listing: Revenue Surges Nearly 30%, H2 Loss Narrows Significantly by Over 90%, Profitability in Sight, Charting a New Course in Native Agentic AI

HONG KONG, March 27, 2026 /PRNewswire/ -- Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and...

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a...

Cyble Secures Dual Industry Honors with Major Wins at Global InfoSec Awards 2026 and Cybersecurity Excellence Awards

Cyble Secures Dual Industry Honors with Major Wins at Global InfoSec Awards 2026 and Cybersecurity Excellence Awards

CUPERTINO, Calif., March 26, 2026 /PRNewswire/ -- Cyble, a global leader in AI-powered cybersecurity solutions, announced major recognition across two of the industry's most prestigious award programs. The company received the Gold Award for Threat...

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to...

  • 1
  • ...
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • ...
  • 266
  • menu
    menu